www.fdanews.com/articles/71312-eu-plan-for-kids-medicines-attacked
EU Plan for Kids' Medicines Attacked
April 20, 2005
Europe's generic drugs industry has slammed European plans to offer an additional six months of patent life to branded medicine makers who develop products for children. The proposed legislation, which is based on the current U.S. model, could come into force early next year if it is approved by the European Parliament and ministers. Greg Perry, director general of the European Generic Medicines Association, said on Tuesday an across-the-board extension of six months to compensate big drug firms for the cost of conducting paediatric drug trials was too generous.